The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Virus Like Particles Market Research Report 2025
Synopsis
The global Virus Like Particles market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Virus Like Particles include GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax and Allergy Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Virus Like Particles, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus Like Particles.
Report Scope
The Virus Like Particles market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Virus Like Particles market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus Like Particles manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Merck
Novavax
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech
Segment by Type
Adeno-Associated Virus
HIV
Hepatitis B Virus
Hepatitis C Virus
Others
Segment by Application
Vaccines
Mycoviruses
Virus Research
Therapeutic and Imaging Agents
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Virus Like Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Virus Like Particles market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Virus Like Particles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Virus Like Particles include GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax and Allergy Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Virus Like Particles, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus Like Particles.
Report Scope
The Virus Like Particles market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Virus Like Particles market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus Like Particles manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Merck
Novavax
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech
Segment by Type
Adeno-Associated Virus
HIV
Hepatitis B Virus
Hepatitis C Virus
Others
Segment by Application
Vaccines
Mycoviruses
Virus Research
Therapeutic and Imaging Agents
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Virus Like Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Virus Like Particles Market Overview
1.1 Product Overview and Scope of Virus Like Particles
1.2 Virus Like Particles Segment by Type
1.2.1 Global Virus Like Particles Market Value Comparison by Type (2024-2030)
1.2.2 Adeno-Associated Virus
1.2.3 HIV
1.2.4 Hepatitis B Virus
1.2.5 Hepatitis C Virus
1.2.6 Others
1.3 Virus Like Particles Segment by Application
1.3.1 Global Virus Like Particles Market Value by Application: (2024-2030)
1.3.2 Vaccines
1.3.3 Mycoviruses
1.3.4 Virus Research
1.3.5 Therapeutic and Imaging Agents
1.3.6 Others
1.4 Global Virus Like Particles Market Size Estimates and Forecasts
1.4.1 Global Virus Like Particles Revenue 2019-2030
1.4.2 Global Virus Like Particles Sales 2019-2030
1.4.3 Global Virus Like Particles Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Virus Like Particles Market Competition by Manufacturers
2.1 Global Virus Like Particles Sales Market Share by Manufacturers (2019-2024)
2.2 Global Virus Like Particles Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Virus Like Particles Average Price by Manufacturers (2019-2024)
2.4 Global Virus Like Particles Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Virus Like Particles, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Virus Like Particles, Product Type & Application
2.7 Virus Like Particles Market Competitive Situation and Trends
2.7.1 Virus Like Particles Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Virus Like Particles Players Market Share by Revenue
2.7.3 Global Virus Like Particles Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Virus Like Particles Retrospective Market Scenario by Region
3.1 Global Virus Like Particles Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Virus Like Particles Global Virus Like Particles Sales by Region: 2019-2030
3.2.1 Global Virus Like Particles Sales by Region: 2019-2024
3.2.2 Global Virus Like Particles Sales by Region: 2025-2030
3.3 Global Virus Like Particles Global Virus Like Particles Revenue by Region: 2019-2030
3.3.1 Global Virus Like Particles Revenue by Region: 2019-2024
3.3.2 Global Virus Like Particles Revenue by Region: 2025-2030
3.4 North America Virus Like Particles Market Facts & Figures by Country
3.4.1 North America Virus Like Particles Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Virus Like Particles Sales by Country (2019-2030)
3.4.3 North America Virus Like Particles Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Virus Like Particles Market Facts & Figures by Country
3.5.1 Europe Virus Like Particles Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Virus Like Particles Sales by Country (2019-2030)
3.5.3 Europe Virus Like Particles Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Virus Like Particles Market Facts & Figures by Country
3.6.1 Asia Pacific Virus Like Particles Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Virus Like Particles Sales by Country (2019-2030)
3.6.3 Asia Pacific Virus Like Particles Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Virus Like Particles Market Facts & Figures by Country
3.7.1 Latin America Virus Like Particles Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Virus Like Particles Sales by Country (2019-2030)
3.7.3 Latin America Virus Like Particles Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Virus Like Particles Market Facts & Figures by Country
3.8.1 Middle East and Africa Virus Like Particles Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Virus Like Particles Sales by Country (2019-2030)
3.8.3 Middle East and Africa Virus Like Particles Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Virus Like Particles Sales by Type (2019-2030)
4.1.1 Global Virus Like Particles Sales by Type (2019-2024)
4.1.2 Global Virus Like Particles Sales by Type (2025-2030)
4.1.3 Global Virus Like Particles Sales Market Share by Type (2019-2030)
4.2 Global Virus Like Particles Revenue by Type (2019-2030)
4.2.1 Global Virus Like Particles Revenue by Type (2019-2024)
4.2.2 Global Virus Like Particles Revenue by Type (2025-2030)
4.2.3 Global Virus Like Particles Revenue Market Share by Type (2019-2030)
4.3 Global Virus Like Particles Price by Type (2019-2030)
5 Segment by Application
5.1 Global Virus Like Particles Sales by Application (2019-2030)
5.1.1 Global Virus Like Particles Sales by Application (2019-2024)
5.1.2 Global Virus Like Particles Sales by Application (2025-2030)
5.1.3 Global Virus Like Particles Sales Market Share by Application (2019-2030)
5.2 Global Virus Like Particles Revenue by Application (2019-2030)
5.2.1 Global Virus Like Particles Revenue by Application (2019-2024)
5.2.2 Global Virus Like Particles Revenue by Application (2025-2030)
5.2.3 Global Virus Like Particles Revenue Market Share by Application (2019-2030)
5.3 Global Virus Like Particles Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Virus Like Particles Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Virus Like Particles Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Novavax
6.3.1 Novavax Corporation Information
6.3.2 Novavax Description and Business Overview
6.3.3 Novavax Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novavax Virus Like Particles Product Portfolio
6.3.5 Novavax Recent Developments/Updates
6.4 Takeda
6.4.1 Takeda Corporation Information
6.4.2 Takeda Description and Business Overview
6.4.3 Takeda Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Virus Like Particles Product Portfolio
6.4.5 Takeda Recent Developments/Updates
6.5 Medicago
6.5.1 Medicago Corporation Information
6.5.2 Medicago Description and Business Overview
6.5.3 Medicago Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Medicago Virus Like Particles Product Portfolio
6.5.5 Medicago Recent Developments/Updates
6.6 MedImmune
6.6.1 MedImmune Corporation Information
6.6.2 MedImmune Description and Business Overview
6.6.3 MedImmune Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.6.4 MedImmune Virus Like Particles Product Portfolio
6.6.5 MedImmune Recent Developments/Updates
6.7 TechnoVax
6.6.1 TechnoVax Corporation Information
6.6.2 TechnoVax Description and Business Overview
6.6.3 TechnoVax Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.4.4 TechnoVax Virus Like Particles Product Portfolio
6.7.5 TechnoVax Recent Developments/Updates
6.8 Agilvax
6.8.1 Agilvax Corporation Information
6.8.2 Agilvax Description and Business Overview
6.8.3 Agilvax Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Agilvax Virus Like Particles Product Portfolio
6.8.5 Agilvax Recent Developments/Updates
6.9 Allergy Therapeutics
6.9.1 Allergy Therapeutics Corporation Information
6.9.2 Allergy Therapeutics Description and Business Overview
6.9.3 Allergy Therapeutics Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Allergy Therapeutics Virus Like Particles Product Portfolio
6.9.5 Allergy Therapeutics Recent Developments/Updates
6.10 Serum Institute of India
6.10.1 Serum Institute of India Corporation Information
6.10.2 Serum Institute of India Description and Business Overview
6.10.3 Serum Institute of India Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Serum Institute of India Virus Like Particles Product Portfolio
6.10.5 Serum Institute of India Recent Developments/Updates
6.11 GeoVax Labs
6.11.1 GeoVax Labs Corporation Information
6.11.2 GeoVax Labs Virus Like Particles Description and Business Overview
6.11.3 GeoVax Labs Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.11.4 GeoVax Labs Virus Like Particles Product Portfolio
6.11.5 GeoVax Labs Recent Developments/Updates
6.12 Cytos Biotechnology
6.12.1 Cytos Biotechnology Corporation Information
6.12.2 Cytos Biotechnology Virus Like Particles Description and Business Overview
6.12.3 Cytos Biotechnology Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Cytos Biotechnology Virus Like Particles Product Portfolio
6.12.5 Cytos Biotechnology Recent Developments/Updates
6.13 ANGANY Genetics
6.13.1 ANGANY Genetics Corporation Information
6.13.2 ANGANY Genetics Virus Like Particles Description and Business Overview
6.13.3 ANGANY Genetics Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.13.4 ANGANY Genetics Virus Like Particles Product Portfolio
6.13.5 ANGANY Genetics Recent Developments/Updates
6.14 CPL Biologicals
6.14.1 CPL Biologicals Corporation Information
6.14.2 CPL Biologicals Virus Like Particles Description and Business Overview
6.14.3 CPL Biologicals Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.14.4 CPL Biologicals Virus Like Particles Product Portfolio
6.14.5 CPL Biologicals Recent Developments/Updates
6.15 Xiamen Innovax Biotech
6.15.1 Xiamen Innovax Biotech Corporation Information
6.15.2 Xiamen Innovax Biotech Virus Like Particles Description and Business Overview
6.15.3 Xiamen Innovax Biotech Virus Like Particles Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
6.15.5 Xiamen Innovax Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Virus Like Particles Industry Chain Analysis
7.2 Virus Like Particles Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Virus Like Particles Production Mode & Process
7.4 Virus Like Particles Sales and Marketing
7.4.1 Virus Like Particles Sales Channels
7.4.2 Virus Like Particles Distributors
7.5 Virus Like Particles Customers
8 Virus Like Particles Market Dynamics
8.1 Virus Like Particles Industry Trends
8.2 Virus Like Particles Market Drivers
8.3 Virus Like Particles Market Challenges
8.4 Virus Like Particles Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Virus Like Particles Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Virus Like Particles Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Virus Like Particles Market Competitive Situation by Manufacturers in 2023
Table 4. Global Virus Like Particles Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global Virus Like Particles Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Virus Like Particles Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Virus Like Particles Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Virus Like Particles Average Price (USD/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Virus Like Particles, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Virus Like Particles, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Virus Like Particles, Product Type & Application
Table 12. Global Key Manufacturers of Virus Like Particles, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Virus Like Particles by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Virus Like Particles as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Virus Like Particles Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Virus Like Particles Sales by Region (2019-2024) & (K Dose)
Table 18. Global Virus Like Particles Sales Market Share by Region (2019-2024)
Table 19. Global Virus Like Particles Sales by Region (2025-2030) & (K Dose)
Table 20. Global Virus Like Particles Sales Market Share by Region (2025-2030)
Table 21. Global Virus Like Particles Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Virus Like Particles Revenue Market Share by Region (2019-2024)
Table 23. Global Virus Like Particles Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Virus Like Particles Revenue Market Share by Region (2025-2030)
Table 25. North America Virus Like Particles Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Virus Like Particles Sales by Country (2019-2024) & (K Dose)
Table 27. North America Virus Like Particles Sales by Country (2025-2030) & (K Dose)
Table 28. North America Virus Like Particles Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Virus Like Particles Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Virus Like Particles Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Virus Like Particles Sales by Country (2019-2024) & (K Dose)
Table 32. Europe Virus Like Particles Sales by Country (2025-2030) & (K Dose)
Table 33. Europe Virus Like Particles Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Virus Like Particles Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Virus Like Particles Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Virus Like Particles Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific Virus Like Particles Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific Virus Like Particles Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Virus Like Particles Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Virus Like Particles Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Virus Like Particles Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America Virus Like Particles Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America Virus Like Particles Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Virus Like Particles Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Virus Like Particles Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Virus Like Particles Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East & Africa Virus Like Particles Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East & Africa Virus Like Particles Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Virus Like Particles Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Virus Like Particles Sales (K Dose) by Type (2019-2024)
Table 51. Global Virus Like Particles Sales (K Dose) by Type (2025-2030)
Table 52. Global Virus Like Particles Sales Market Share by Type (2019-2024)
Table 53. Global Virus Like Particles Sales Market Share by Type (2025-2030)
Table 54. Global Virus Like Particles Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Virus Like Particles Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Virus Like Particles Revenue Market Share by Type (2019-2024)
Table 57. Global Virus Like Particles Revenue Market Share by Type (2025-2030)
Table 58. Global Virus Like Particles Price (USD/Dose) by Type (2019-2024)
Table 59. Global Virus Like Particles Price (USD/Dose) by Type (2025-2030)
Table 60. Global Virus Like Particles Sales (K Dose) by Application (2019-2024)
Table 61. Global Virus Like Particles Sales (K Dose) by Application (2025-2030)
Table 62. Global Virus Like Particles Sales Market Share by Application (2019-2024)
Table 63. Global Virus Like Particles Sales Market Share by Application (2025-2030)
Table 64. Global Virus Like Particles Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Virus Like Particles Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Virus Like Particles Revenue Market Share by Application (2019-2024)
Table 67. Global Virus Like Particles Revenue Market Share by Application (2025-2030)
Table 68. Global Virus Like Particles Price (USD/Dose) by Application (2019-2024)
Table 69. Global Virus Like Particles Price (USD/Dose) by Application (2025-2030)
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Business Overview
Table 72. GlaxoSmithKline Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 73. GlaxoSmithKline Virus Like Particles Product
Table 74. GlaxoSmithKline Recent Developments/Updates
Table 75. Merck Corporation Information
Table 76. Merck Description and Business Overview
Table 77. Merck Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 78. Merck Virus Like Particles Product
Table 79. Merck Recent Developments/Updates
Table 80. Novavax Corporation Information
Table 81. Novavax Description and Business Overview
Table 82. Novavax Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 83. Novavax Virus Like Particles Product
Table 84. Novavax Recent Developments/Updates
Table 85. Takeda Corporation Information
Table 86. Takeda Description and Business Overview
Table 87. Takeda Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 88. Takeda Virus Like Particles Product
Table 89. Takeda Recent Developments/Updates
Table 90. Medicago Corporation Information
Table 91. Medicago Description and Business Overview
Table 92. Medicago Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 93. Medicago Virus Like Particles Product
Table 94. Medicago Recent Developments/Updates
Table 95. MedImmune Corporation Information
Table 96. MedImmune Description and Business Overview
Table 97. MedImmune Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 98. MedImmune Virus Like Particles Product
Table 99. MedImmune Recent Developments/Updates
Table 100. TechnoVax Corporation Information
Table 101. TechnoVax Description and Business Overview
Table 102. TechnoVax Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 103. TechnoVax Virus Like Particles Product
Table 104. TechnoVax Recent Developments/Updates
Table 105. Agilvax Corporation Information
Table 106. Agilvax Description and Business Overview
Table 107. Agilvax Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 108. Agilvax Virus Like Particles Product
Table 109. Agilvax Recent Developments/Updates
Table 110. Allergy Therapeutics Corporation Information
Table 111. Allergy Therapeutics Description and Business Overview
Table 112. Allergy Therapeutics Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 113. Allergy Therapeutics Virus Like Particles Product
Table 114. Allergy Therapeutics Recent Developments/Updates
Table 115. Serum Institute of India Corporation Information
Table 116. Serum Institute of India Description and Business Overview
Table 117. Serum Institute of India Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 118. Serum Institute of India Virus Like Particles Product
Table 119. Serum Institute of India Recent Developments/Updates
Table 120. GeoVax Labs Corporation Information
Table 121. GeoVax Labs Description and Business Overview
Table 122. GeoVax Labs Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 123. GeoVax Labs Virus Like Particles Product
Table 124. GeoVax Labs Recent Developments/Updates
Table 125. Cytos Biotechnology Corporation Information
Table 126. Cytos Biotechnology Description and Business Overview
Table 127. Cytos Biotechnology Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 128. Cytos Biotechnology Virus Like Particles Product
Table 129. Cytos Biotechnology Recent Developments/Updates
Table 130. ANGANY Genetics Corporation Information
Table 131. ANGANY Genetics Description and Business Overview
Table 132. ANGANY Genetics Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 133. ANGANY Genetics Virus Like Particles Product
Table 134. ANGANY Genetics Recent Developments/Updates
Table 135. CPL Biologicals Corporation Information
Table 136. CPL Biologicals Description and Business Overview
Table 137. CPL Biologicals Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 138. CPL Biologicals Virus Like Particles Product
Table 139. CPL Biologicals Recent Developments/Updates
Table 140. Xiamen Innovax Biotech Corporation Information
Table 141. Xiamen Innovax Biotech Description and Business Overview
Table 142. Xiamen Innovax Biotech Virus Like Particles Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 143. Xiamen Innovax Biotech Virus Like Particles Product
Table 144. Xiamen Innovax Biotech Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Virus Like Particles Distributors List
Table 148. Virus Like Particles Customers List
Table 149. Virus Like Particles Market Trends
Table 150. Virus Like Particles Market Drivers
Table 151. Virus Like Particles Market Challenges
Table 152. Virus Like Particles Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Virus Like Particles
Figure 2. Global Virus Like Particles Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Virus Like Particles Market Share by Type in 2023 & 2030
Figure 4. Adeno-Associated Virus Product Picture
Figure 5. HIV Product Picture
Figure 6. Hepatitis B Virus Product Picture
Figure 7. Hepatitis C Virus Product Picture
Figure 8. Others Product Picture
Figure 9. Global Virus Like Particles Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Virus Like Particles Market Share by Application in 2023 & 2030
Figure 11. Vaccines
Figure 12. Mycoviruses
Figure 13. Virus Research
Figure 14. Therapeutic and Imaging Agents
Figure 15. Others
Figure 16. Global Virus Like Particles Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Virus Like Particles Market Size (2019-2030) & (US$ Million)
Figure 18. Global Virus Like Particles Sales (2019-2030) & (K Dose)
Figure 19. Global Virus Like Particles Average Price (USD/Dose) & (2019-2030)
Figure 20. Virus Like Particles Report Years Considered
Figure 21. Virus Like Particles Sales Share by Manufacturers in 2023
Figure 22. Global Virus Like Particles Revenue Share by Manufacturers in 2023
Figure 23. The Global 5 and 10 Largest Virus Like Particles Players: Market Share by Revenue in 2023
Figure 24. Virus Like Particles Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 25. Global Virus Like Particles Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 26. North America Virus Like Particles Sales Market Share by Country (2019-2030)
Figure 27. North America Virus Like Particles Revenue Market Share by Country (2019-2030)
Figure 28. U.S. Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Canada Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Europe Virus Like Particles Sales Market Share by Country (2019-2030)
Figure 31. Europe Virus Like Particles Revenue Market Share by Country (2019-2030)
Figure 32. Germany Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. France Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. U.K. Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Italy Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Russia Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Asia Pacific Virus Like Particles Sales Market Share by Region (2019-2030)
Figure 38. Asia Pacific Virus Like Particles Revenue Market Share by Region (2019-2030)
Figure 39. China Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Japan Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. South Korea Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. India Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Australia Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Taiwan Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Indonesia Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Thailand Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Malaysia Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Philippines Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Latin America Virus Like Particles Sales Market Share by Country (2019-2030)
Figure 50. Latin America Virus Like Particles Revenue Market Share by Country (2019-2030)
Figure 51. Mexico Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Brazil Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Argentina Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Middle East & Africa Virus Like Particles Sales Market Share by Country (2019-2030)
Figure 55. Middle East & Africa Virus Like Particles Revenue Market Share by Country (2019-2030)
Figure 56. Turkey Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Saudi Arabia Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. U.A.E Virus Like Particles Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 59. Global Sales Market Share of Virus Like Particles by Type (2019-2030)
Figure 60. Global Revenue Market Share of Virus Like Particles by Type (2019-2030)
Figure 61. Global Virus Like Particles Price (USD/Dose) by Type (2019-2030)
Figure 62. Global Sales Market Share of Virus Like Particles by Application (2019-2030)
Figure 63. Global Revenue Market Share of Virus Like Particles by Application (2019-2030)
Figure 64. Global Virus Like Particles Price (USD/Dose) by Application (2019-2030)
Figure 65. Virus Like Particles Value Chain
Figure 66. Virus Like Particles Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
